BeyondSpring, Inc. (BYSI) Q4 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to BeyondSpring's fourth quarter and year-end 2021 financial results conference call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a brief question-and-answer session. As a reminder, this call is being recorded today, April 14, 2022. I will now turn the call over to Ashley Sergio of LifeSciAdvisors. Thank you, everyone, for joining today's call. I would like to advise listeners that comments made on today's call may reflect forward-looking statements that are related to such matters as BeyondSpring's clinical and preclinical research and development activities and results, regulatory and commercial plans, industry trends, market potential, collaborative initiatives, and other financial projections, among others. While management believes that its assumptions, expectations, and projections are reasonable in the view of the currently available information, you are cautioned not to place undue reliance on these forward-looking statements. The company's actual results may differ materially from those discussed during this call for a variety of reasons, including those described in the forward-looking statements and risk factors sections of the company's 20-F and other filings with the SEC, which are available on the investor section of BeyondSpring's website. Joining us on today's call is Dr. Lan Huang, BeyondSpring's co-founder, chairman, and chief executive officer, Dr. Ramon Mohanlal, executive vice president, research and development, and chief medical officer, and Elizabeth Serpak, chief financial officer. It is now my pleasure to turn the call over to Dr. Lan Huang. Good morning, everyone, and thank you for joining today's call. It's a pleasure to be here today reporting our ...